Pharmaceutical standardization of Vasa Avaleha and its granules with their efficacy on Tamaka Shwasa (Bronchial Asthma)

Institute for post gradute teaching and research in ayurved0 个研究点目标入组 60 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Both the sexes having age between 12 years to 70 years
•2.Mild persistent cases of Asthma (as per WHO GINA Guideline) of duration more than 6 months.
•3.Symptoms/exacerbation (Wheeze, cough and breathlessness) greater than weekly and less than daily in frequency.
•4.Night symptoms twice per month but less than once a week.

•1.Age more than 70 years and below 12 years.
•2.Mild intermittent, Moderated persistent, severe persistent to severe Asthma.
•3.Dyspnoea resulting from other diseases like left ventricular failure, COPD (Chronic Bronchitis, Emphysema), upper respiratory tract obstruction, bronchiectasis, cases of tuberculosis, interstitial lung disease/occupational lung disease, tropical pulmonary eosinophilia & allergic bronchopulmonary aspergillosis etc.
•4.Patients having anaemia, pneumonia, tuberculosis, lung cancer, lung abscess and other such complicated conditions.
•5.Patients having diabetes, hypertension, Chronic and Acute renal failure etc. conditions in which urination is markedly diminished or excessive were excluded.
•6.HIV positive cases.
•7.Pregnant/lactating mother.
•8.Patients who need Salbutamol inhaler daily.
•9.Patients having classical symptoms of Maha, Urdha, Chhinna and Kshudra Shwasa.

发起方

Institute for post gradute teaching and research in ayurved